drugset
drugset / Trial / NCT03602781

Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric

NCT03602781 ↗

Phase 3 Withdrawn Bellerophon Pulse Technologies Worldwide Clinical Trials · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of PAH Subjects with LTOT Use that have Demonstrated Improved Exercise Tolerance with the use of Inhaled Nitric Oxide

Timeline

Start
2018-08
Primary completion
2019-06
Completion
2020-06

Outcome

Outcome not reported

Stopped: “Decision not to proceed with Study”

Drugs

EvaluationDrugModalityDoseRoute
Comparator iNO Unknown 75 ug/kg Inhaled

Indications

pulmonary arterial hypertension